| Literature DB >> 34697917 |
Oliver Glass1, Daniel Liu2, Elizabeth Bechard3, Cynthia D Guy4, Jane Pendergast5, Anna Mae Diehl6, Manal F Abdelmalek6.
Abstract
Exercise is a foundational treatment for nonalcoholic fatty liver disease (NAFLD); however, the majority of patients are unable to initiate and maintain effective exercise habits and remain at increased risk for progressive liver disease. Barriers and limitations to exercise in patients with NAFLD have not been fully identified. We performed a single survey of 94 patients with biopsy-proven NAFLD to understand baseline physical activity and sedentary behavior, self-perceived fitness, limitations to exercise, potential solutions to increase physical activity behavior, and perception of exercise as a foundational treatment for NAFLD. For exploratory analyses, we evaluated differences in responses to the survey by grouping severity of hepatic fibrosis as follows: nonalcoholic fatty liver (NAFL); early stage (nonalcoholic steatohepatitis [NASH] F0, NASH F1, NASH F2); and late stage (NASH F3, NASH F4). Zero weekly total physical activity was reported by 29% of patients with NAFLD. Late-stage NASH had significantly lower vigorous (P = 0.024), walking (P = 0.029), total weekly activity (P = 0.043), and current fitness level (P = 0.022) compared to early stage NASH. Overall, 72% of patients with NAFLD reported limitations to exercise, with the greatest proportion citing lack of energy (62%), fatigue (61%), prior/current Injury (50%), and shortness of breath (49%). A preference for personal training to increase their physical activity was indicated by 66% of patients with NAFLD, and 63% preferred exercise over medication to treat NAFLD.Entities:
Mesh:
Year: 2021 PMID: 34697917 PMCID: PMC8793987 DOI: 10.1002/hep4.1808
Source DB: PubMed Journal: Hepatol Commun ISSN: 2471-254X
Patient Characteristics of the 94 Survey Participants
| NAFLD n = 94 | NAFL n = 12 | Early Stage (NASH F0, F1, F2) n = 23 | Late Stage (NASH F3, F4) n = 59 |
| |
|---|---|---|---|---|---|
| Age, mean (SD) | 58 (11) | 51 (15) | 58 (10) | 60 (10) | 0.028 |
| Sex | 0.150 | ||||
| Male, n (%) | 54 (57) | 2 (17) | 11 (48) | 27 (46) | |
| Race, n (%) | 0.571 | ||||
| Caucasian | 84 (89) | 10 (83) | 21 (91) | 53 (90) | |
| African American | 6 (6) | 1 (8) | 1 (4) | 4 (7) | |
| American Indian/Alaskan Native | 1 (1) | 0 | 0 | 1 (2) | |
| Asian | 1 (1) | 0 | 1 (4) | 0 | |
| Other | 2 (2) | 1 (8) | 0 | 1 (2) | |
| Ethnicity | 0.118 | ||||
| Hispanic | 5 (5) | 2 (17) | 0 | 3 (5) | |
| Non‐Hispanic | 87 (93) | 10 (83) | 23 (100) | 54 (92) | |
| NA | 2 (2) | 2 (3) | |||
| BMI (kg/m2), mean (SD) | 34.3 (5.2) | 34.9 (6.3) | 32.2 (4) | 35 (5.3) | 0.094 |
| Smoking status, n (%) | 0.811 | ||||
| Smoker | 6 (6) | 1 (8) | 2 (9) | 3 (5) | |
| Nonsmoker | 87 (93) | 11 (92) | 21 (91) | 55 (93) | |
| Unknown | 1 (1) | 0 | 0 | 1 (2) | |
| Diabetes status | |||||
| Diabetic, n (%) | 49 (52) | 5 (42) | 7 (30) | 37 (63) | |
| Prediabetic, n (%) | 7 (7) | 1 (8) | 5 (22) | 1 (2) | |
| Nondiabetic, n (%) | 38 (40) | 6 (50) | 11 (48) | 21 (36) | |
| AST (U/L), mean (SD) | 47 (24) | 46 (28.8) | 40.7 (21.7) | 49.7 (23.8) | 0.346 |
| ALT(U/L), mean (SD) | 50.4 (34.2) | 65.1 (45.5) | 56.7 (40) | 44.8 (27.6) | 0.111 |
| NAFLD diagnosis, n (%) | |||||
| NAFL | 12 (13) | 12 | 0 | 0 | |
| NASH F0 | 4 (4) | 0 | 4 | 0 | |
| NASH F1 | 8 (9) | 0 | 8 | 0 | |
| NASH F2 | 11 (12) | 0 | 11 | 0 | |
| NASH F3 | 22 (23) | 0 | 0 | 22 | |
| NASH F4 | 37 (39) | 0 | 0 | 37 |
Abbreviation: NA, not answered.
FIG. 1Weekly physical activity by METs and sedentary behavior in patients with NAFLD. (A) Weekly vigorous, moderate, and walking METs in patients with NAFLD (n = 94). (B) Total weekly METs in patients with NAFLD. (C) Total weekly METs by NAFL, early stage NASH, and late‐stage NASH. (D) Weekly vigorous METs by NAFL, early stage NASH, and late‐stage NASH. (E) Weekly moderate METs by NAFL, early stage NASH, and late‐stage NASH. (F) Weekly walking METs by NAFL, early stage NASH, and late‐stage NASH. (G) Total daily hours spent sitting in patients with NAFLD. (H) Total daily hours spent sitting by NAFL, early stage NASH, and late‐stage NASH. Box plots show median (bold horizontal line), interquartile range (box), third quartile (upper limit of box), and first quartile (lower limit of box). Dashed lines indicate data range; horizontal lines show minimum (bottom) and maximum (top) values.
FIG. 2Fitness levels and fitness‐related services that would increase the desire and/or ability for patients with NAFLD to be more physically active. (A) Current, best, and importance of fitness in NAFL, early stage NASH, and late‐stage NASH, using a 1‐10 scale. Means are presented with SD; *P < 0.05. (B) Proportion of responses to fitness‐related services from patients with NAFLD.
Limitations to Physical Activity and Exercise in Patients With NAFLD
| NAFLD (n = 94) | NAFL (n = 12) | Early Stage (n = 23) | Late Stage (n = 59) |
| |
|---|---|---|---|---|---|
| Limitations to physical activity/exercise, % yes | 72 | 86 | 57 | 77 | 0.170 |
| Limitations of physical activity/exercise due to medications, % yes | 27 | 50 | 22 | 24 | 0.215 |
|
| |||||
| Pain | 44 | 58 | 48 | 39 | 0.420 |
| Physical ability | 46 | 50 | 44 | 51 | 0.228 |
| Fatigue | 61 | 67 | 52 | 63 | 0.613 |
| Discomfort | 47 | 67 | 43 | 44 | 0.333 |
| Lack of energy | 62 | 67 | 39 | 69 | 0.036 |
| Cost | 17 | 17 | 4 | 22 | 0.160 |
| Time | 31 | 25 | 39 | 27 | 0.524 |
| Lack of access | 7 | 8 | 4 | 8 | 0.809 |
| Lack of interest | 32 | 8 | 35 | 36 | 0.172 |
| Lack of enjoyment | 31 | 17 | 44 | 32 | 0.809 |
| Prior/current injury | 50 | 50 | 57 | 47 | 0.762 |
| Shortness of breath | 49 | 58 | 17 | 59 | 0.002 |
| No limitations to exercise | 7 | 8 | 13 | 6 | 0.464 |
P value significant at <0.05.
Preference for Exercise, Medication, or Neither as Treatment for NAFLD
| Response Choice | Proportion Yes, % |
|---|---|
| Exercise | |
| No medication side effects | 63 |
| Mild medication side effects | 68 |
| Moderate medication side effects | 88 |
| Severe medication side effects | 94 |
| Medication | |
| No medication side effects | 36 |
| Mild medication side effects | 27 |
| Moderate medication side effects | 7 |
| Severe medication side effects | 1 |
| Neither | |
| No medication side effects | 1 |
| Mild medication side effects | 5 |
| Moderate medication side effects | 4 |
| Severe medication side effects | 5 |
Univariate Analysis of Factors Associated with Total Weekly METs in Patients with NAFLD
| Continuous Predictors |
|
|
|---|---|---|
| Age | −0.38 | 0.0002 |
| BMI | −0.11 | 0.318 |
| AST | 0.09 | 0.407 |
| ALT | 0.30 | 0.005 |
| Sit time | −0.30 | 0.003 |
| Number of limitations to physical activity/exercise | −0.26 | 0.010 |
| Current overall fitness | 0.36 | 0.0004 |
| Importance of fitness | 0.18 | 0.084 |
| Best fitness level | 0.07 | 0.491 |
| Categorical Predictors | Test Statistic |
|
| Sex (M/F) | 3.54 | 0.060 |
| Race | 1.92 | 0.750 |
| Ethnicity | 0.23 | 0.631 |
| Smoking status | 0.07 | 0.788 |
| Diabetes status | 1.9 | 0.386 |
| NAFLD stage (NAFL, early stage, late stage) | 5.82 | 0.054 |
| Limitation to physical activity/exercise | 11.67 | 0.003 |
| Specific limitation | ||
|
Pain | 2.75 | 0.097 |
|
Physical ability | 4.05 | 0.044 |
|
Fatigue | 4.77 | 0.029 |
|
Discomfort | 5.00 | 0.025 |
|
Lack of energy | 8.60 | 0.003 |
|
Cost | 0.05 | 0.815 |
|
Lack of time | 2.50 | 0.114 |
|
Lack of access | 1.63 | 0.202 |
|
Lack of interest | 2.20 | 0.138 |
|
Lack of enjoyment | 0.26 | 0.607 |
|
Prior/current injury | −2.37 | 0.124 |
|
Shortness of breath | 4.64 | 0.031 |
P value significant at <0.05.
Abbreviations: F, female; M, male.
Multivariate Analysis of Factors Associated with Total Weekly METs in Patients with NAFLD
| Estimate | SE | 95% CI | Chi‐Square |
| |
|---|---|---|---|---|---|
| Age | −0.05 | 0.01 | −0.07 to 0.02 | 13.69 | 0.0002 |
| BMI | −0.05 | 0.03 | −0.11 to 0.01 | 2.51 | 0.113 |
| Early stage (vs. NAFL) | 1.30 | 0.41 | 0.50‐2.10 | 10.23 | 0.001 |
| Late stage (vs. NAFL) | 1.00 | 0.37 | 0.27‐1.72 | 7.16 | 0.007 |
| Diabetes (vs. prediabetes) | 0.50 | 0.51 | −0.49 to 1.49 | 0.97 | 0.325 |
| No diabetes (vs. prediabetes) | 0.45 | 0.48 | −0.48 to 1.39 | 0.91 | 0.341 |
| Sit time | 0.01 | 0.001 | −0.001 to 0.001 | 0.02 | 0.886 |
| Current fitness | 0.16 | 0.08 | −0.002‐0.31 | 3.72 | 0.054 |
| Importance of fitness | −0.05 | 0.07 | −0.18 to 0.09 | 0.45 | 0.502 |
| Vigorous activity (yes) | 0.74 | 0.65 | −0.53 to 2.00 | 1.31 | 0.253 |
| Moderate activity (yes) | 0.27 | 0.59 | −0.88 to 1.41 | 0.21 | 0.651 |
| Medication limitation | 0.36 | 0.34 | −0.31 to 1.03 | 1.1 | 0.294 |
| Total number of limitations | −0.06 | 0.05 | −0.16 to 0.04 | 1.27 | 0.261 |
| Intercept | 9.87 | 1.74 | 6.46‐13.27 | 32.29 | <0.001 |
| Scale parameter | 1.35 | 0.22 | 0.99‐1.84 |
P value significant at <0.05.
Abbreviations: CI, confidence interval; SE, standard error.